Stephan Braun was named chief medical officer of ImCheck Therapeutics.
A multidisciplinary team of doctors at Mayo Clinic in Arizona performed the third known total larynx transplant in the U.S.
Genentech, a member of the Roche Group, announced that the phase II/III SKYSCRAPER-06 study evaluating tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival at its primary analysis with a hazard ratio of 1.27 [95% CI: 1.02,1.57] and overall survival at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature.
Chemotherapy is known to cause behavioral side effects, including cognitive decline. Notably, the gut microbiome communicates with the brain to affect behavior, including cognition.
With the number of adult cancer survivors in the United States expected to reach 23 million by 2032, the long-term needs of this population are growing yet often poorly understood and addressed.
Using genetic engineering techniques, investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Cancer Immunotherapy have designed a novel type of cell to recognize and fight cancer.
Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.
FDA granted Fast Track designation for 225Ac-FL-020, a radiopharmaceutical which targets prostate-specific membrane antigen for the treatment of metastatic castration-resistant prostate cancer.
Boehringer Ingelheim and OSE Immunotherapeutics SA, a clinical-stage biotech company, announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology program into the next phase in clinical development.
The Wistar Institute is collaborating with Accelerated Biosciences Corp. to create a platform based on human trophoblast stem cells to explore new immunotherapies that use Accelerated Bio’s proprietary technology. This collaboration could generate various types of immune cells from hTSCs, changing the field of allogeneic immunotherapies.
